Structural modification of receptor-binding technetium-99m complexes in order to improve brain uptake

European Journal of Nuclear Medicine

Volumn 24, Issue 3, 1997, Pages 316-319

  Johannsen, Bernd ^a   Berger, Ralf ^a   Brust, Peter ^a   Pietzsch, Hans Juergen ^a   Scheunemann, Matthias ^a   Seifert, Sepp ^a   Spies, Hartmut ^a   Syhre, Rosemarie ^a  

^a INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

Author keywords

Blood brain barrier; Brain uptake; Lipophilicity; pK(a) values; Serotonin receptor binding; Technetium 99m complexes

Indexed keywords

BRAIN RECEPTOR; ETHER; NITROGEN; OXYGEN; SEROTONIN 2A RECEPTOR; TECHNETIUM 99M;

ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BLOOD PH; BRAIN; CONTROLLED STUDY; DIAGNOSTIC IMAGING; INTRAVENOUS DRUG ADMINISTRATION; IONIZATION; LIPOPHILICITY; NONHUMAN; RAT; RECEPTOR BINDING;

EID: 0030945997     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF01728770     Document Type: Article

References (15)

1. 99m/99Tc-DADT-benzovesamicol: a potential marker for cholinergic neurons. Nucl Med Biol 1994; 21: 197-203.
2. 1A receptor imaging agents. Eleventh International Symposium on Radiopharmaceutical Chemistry, Vancouver; Abstracts. 1995: 306-308.
3. 99mTc-BUP-BAT: possible ligands for dopamine receptor imaging with SPECT. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine. Padova: SGEditoriali; 1995: 569-572.
4. Baidoo KE, Scheffel U, Lever SZ, Stathis M, Wagner HN Jr. Serotonin-1A receptor binding technetium-99m-labeled complexes. J Nucl Med 1995; 36: 28P.
5. Lever SZ, Baidoo KE, Mahmood A, Matsumura K, Scheffel U, Wagner HN Jr. Novel technetium ligands with affinity for the muscarinic cholinergic receptor. Nucl Med Biol 1994; 21: 157-164.
6. 99mTc complex as a dopamine transporter imaging agent. J Am Chem Soc 1995; 117: 11037-11038.
7. 99mtechnetium probe to label the dopamine transporter in brain by SPECT imaging. Synapse 1996; 22: 239-246.
8. Pietzsch HJ, Spies H, Hoffmann S. Lipophilic Tc complexes. VI. Neutral oxotechnetium(V) complexes with monothiol/tridentate dithiol coordination. Inorg Chim Acta 1989; 165: 163-166.
9. Spies H, Pietzsch HJ, Hoffmann S, Münze R. Verfahren zur Herstellung neutraler Komplexe des Technetiums. Patent 1988: DD 279 023.
10. Spies H, Fietz T, Glaser M, Pietzsch HJ, Johannsen B. The n+1 concept in the synthesis strategy of novel technetium and rhenium tracers. In: Nicolini M, Bandoli G, Mazzi U, eds. Technetium and rhenium in chemistry and nuclear medicine. Padova: SGEditoriali; 1995: 243-246.
11. Johannsen B, Pietzsch HJ, Scheunemann M, Spies H, Brust P. Oxotechnetium(V) and oxorhenium(V) complexes as potential imaging agents for the serotonin receptor. J Nucl Med 1995; 36: 27P.
12. 2A serotonin receptor binding: structure-affinity considerations. Nucl Med Biol 1996; 23: 429-438.
13. Eckelman WC. Radiolabeling with technetium-99m to study high-capacity and low-capacity biochemical systems. Eur J Nucl Med 1995; 22: 249-263.
14. Nowotnik DP, Technetium-based brain perfusion agents. In: Nunn A, ed Radiopharmaceuticals: chemistry and pharmacology. New York: Marcel Dekker, 1992: 37-95.
15. 2 complexes for developing new brain imaging agents. Eleventh International Symposium on Radiopharmaceutical Chemistry, Vancouver: Abstracts. 1995: 782-784.